At Alseres Pharmaceuticals, we're passionate about improving people's lives. We are a biopharmaceutical company focused on developing safe, innovative drugs using ground-breaking regenerative technologies targeted to traumatic injury and degenerative disease. Whether we're conducting clinical trials, collaborating with our business partners, or fostering physician and patient relationships, everyone at Alseres shares a commitment to find a better solution—and make it available to those who need it most.
On June 11, 2007, BLSI began trading as ALSE on the NASDAQ Capital Market.
Learn More
Peter Savas explains the company's rebranding strategy.
Learn More
The clinical trial of Cethrin in acute spinal cord injury continues.
Learn More